[⁶⁸Ga]Ga-PSMA-11 PET/CT and [¹⁸F]Fluorocholine PET/CT in Assessment and Clinical Decision Making of Recurrent Prostate Cancer: A Prospective Crossover Trial.

ABSTRACT:

Purpose

There are few prospective studies addressed toward the role of ⁶⁸Gallium-labelled prostate-specific membrane antigen-11 ([⁶⁸Ga]Ga-PSMA-11) compared to [¹⁸F]Fluorocholine ([¹⁸F]FCH) PET/CT in clinical decision-making as prostate-specific PET-tracers. This study aims to evaluate the impact of PET/CT using [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FCH in clinical management of recurrent prostate cancer (PCa) and correlates imaging findings with clinical characteristics of PCa.

Procedures

Forty-six patients with PCa (mean age 68.3 ± 6.3 years) with biochemical recurrence were enrolled in this prospective crossover trial. All patients underwent both [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FCH PET/CT within a maximu

SUBMITTER: Beheshti M 

PROVIDER: S-EPMC12405339 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature